AU2019296320B2 - Complex for enhancing immune response - Google Patents

Complex for enhancing immune response Download PDF

Info

Publication number
AU2019296320B2
AU2019296320B2 AU2019296320A AU2019296320A AU2019296320B2 AU 2019296320 B2 AU2019296320 B2 AU 2019296320B2 AU 2019296320 A AU2019296320 A AU 2019296320A AU 2019296320 A AU2019296320 A AU 2019296320A AU 2019296320 B2 AU2019296320 B2 AU 2019296320B2
Authority
AU
Australia
Prior art keywords
pamica
complex
antigen
group
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019296320A
Other languages
English (en)
Other versions
AU2019296320A1 (en
Inventor
Haixiang Lin
Fang Liu
Li ZHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Yisheng Biotechnology Co Ltd
Original Assignee
Beijing Yisheng Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810698033.6A external-priority patent/CN108743938B/zh
Priority claimed from CN201810700708.6A external-priority patent/CN109078180B/zh
Application filed by Beijing Yisheng Biotechnology Co Ltd filed Critical Beijing Yisheng Biotechnology Co Ltd
Publication of AU2019296320A1 publication Critical patent/AU2019296320A1/en
Application granted granted Critical
Publication of AU2019296320B2 publication Critical patent/AU2019296320B2/en
Assigned to Beijing Yisheng Biotechnology Co., Ltd. reassignment Beijing Yisheng Biotechnology Co., Ltd. Request for Assignment Assignors: Xinfu (Beijing) Medical Technology Co., Ltd.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AU2019296320A 2018-06-29 2019-06-28 Complex for enhancing immune response Active AU2019296320B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810700708.6 2018-06-29
CN201810698033.6A CN108743938B (zh) 2018-06-29 2018-06-29 用于增强免疫响应的复合物的制备方法
CN201810698033.6 2018-06-29
CN201810700708.6A CN109078180B (zh) 2018-06-29 2018-06-29 用于增强免疫响应的复合物
PCT/CN2019/093558 WO2020001587A1 (zh) 2018-06-29 2019-06-28 用于增强免疫响应的复合物

Publications (2)

Publication Number Publication Date
AU2019296320A1 AU2019296320A1 (en) 2021-01-28
AU2019296320B2 true AU2019296320B2 (en) 2023-10-12

Family

ID=68984509

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019296320A Active AU2019296320B2 (en) 2018-06-29 2019-06-28 Complex for enhancing immune response

Country Status (11)

Country Link
US (2) US12178871B2 (cg-RX-API-DMAC7.html)
EP (2) EP3818990A4 (cg-RX-API-DMAC7.html)
JP (2) JP7296644B2 (cg-RX-API-DMAC7.html)
KR (2) KR102631084B1 (cg-RX-API-DMAC7.html)
AU (1) AU2019296320B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020026976A2 (cg-RX-API-DMAC7.html)
CA (2) CA3105281A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021000002A (cg-RX-API-DMAC7.html)
SG (2) SG11202013185VA (cg-RX-API-DMAC7.html)
WO (2) WO2020001596A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100026B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7296644B2 (ja) 2018-06-29 2023-06-23 信福(北京)医▲薬▼科技有限公司 免疫応答を強化するための複合物の調製方法
WO2025076078A1 (en) * 2023-10-03 2025-04-10 The General Hospital Corporation Methods of central nervous system administration of compositions comprising a cell therapy and dimethyl sulfoxide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599071A (zh) * 2013-11-08 2014-02-26 杭州美亚药业有限公司 一种双链聚肌胞干粉的制备方法
WO2017080098A1 (zh) * 2015-11-10 2017-05-18 林海祥 皮氨钙佐剂及含有皮氨钙佐剂的疫苗

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056315C (zh) 1993-05-31 2000-09-13 林海祥 聚肌胞复合物免疫佐剂及含有该佐剂的疫苗
ES2259914B1 (es) 2005-03-14 2007-06-16 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
CN103405762A (zh) * 2005-06-08 2013-11-27 依生生物制药(新加坡)私人有限公司 以聚肌苷酸-聚胞苷酸为主的佐剂
KR101203401B1 (ko) 2005-06-08 2012-11-22 이쉥 바이오파마(싱가포르)피티이 리미티드 폴리이노신산-폴리시티딜산-기초 보조제
US20070166239A1 (en) 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
US20070166800A1 (en) 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
CN101134014A (zh) 2007-09-19 2008-03-05 天津大学 带有表面涂层的硫酸钙串珠植入型局部释药体系及制备方法
CN101293933B (zh) 2008-06-17 2011-05-04 浙江大学 聚乙二醇修饰壳寡糖脂肪酸嫁接物及制备方法和应用
CN102318740B (zh) 2011-07-15 2012-11-21 山东省农业科学院畜牧兽医研究所 复合氨基酸多维液体微乳及其制备方法
SG11201406208QA (en) 2012-05-03 2014-11-27 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
EP3083962B1 (en) * 2013-12-16 2021-08-18 RiboxX GmbH Double-stranded polyc:poly(g/i) rna for immunostimulation and cancer treatment
CN104434784B (zh) 2014-11-15 2017-07-04 成都天台山制药有限公司 聚肌胞注射液药物组合物和制法
CN107184973A (zh) 2016-03-15 2017-09-22 中国医学科学院基础医学研究所 一种复合疫苗佐剂及其应用
CN106075431A (zh) 2016-03-23 2016-11-09 林海祥 皮氨钙联合佐剂及含有皮氨钙联合佐剂的疫苗
US10512687B2 (en) 2016-04-01 2019-12-24 Colorado State University Research Foundation Compositions and methods for enhanced innate immunity
CN107875168B (zh) * 2016-09-30 2022-03-04 广州百吉生物制药有限公司 一种免疫调节组合物在治疗恶性积液中的用途
RU2647366C1 (ru) 2017-04-12 2018-03-15 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук" (ФИЦ Биотехнологии РАН) Антиагрегантное средство
CN109125264B (zh) 2017-06-19 2020-10-30 林海祥 一种抗感染抗肿瘤的粘膜免疫制剂
CN109078180B (zh) * 2018-06-29 2019-05-31 信福(北京)医药科技有限公司 用于增强免疫响应的复合物
JP7296644B2 (ja) 2018-06-29 2023-06-23 信福(北京)医▲薬▼科技有限公司 免疫応答を強化するための複合物の調製方法
CN108743938B (zh) 2018-06-29 2019-04-09 信福(北京)医药科技有限公司 用于增强免疫响应的复合物的制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599071A (zh) * 2013-11-08 2014-02-26 杭州美亚药业有限公司 一种双链聚肌胞干粉的制备方法
WO2017080098A1 (zh) * 2015-11-10 2017-05-18 林海祥 皮氨钙佐剂及含有皮氨钙佐剂的疫苗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAVALIAUSKIS, A. ET AL: "Use of Poly(I:C) Stabilized with Chitosan As a Vaccine-Adjuvant Against Viral Hemorrhagic Septicemia Virus Infection in Zebrafish", vol. 12, no. 6, 1 December 2015, pages 421 - 431 *

Also Published As

Publication number Publication date
ZA202100026B (en) 2021-10-27
US12226477B2 (en) 2025-02-18
KR20210025095A (ko) 2021-03-08
KR102631084B1 (ko) 2024-01-29
EP3818990A4 (en) 2022-05-04
JP7366434B2 (ja) 2023-10-23
JP2021529787A (ja) 2021-11-04
KR20210025096A (ko) 2021-03-08
SG11202013185VA (en) 2021-01-28
US20240316189A9 (en) 2024-09-26
EP3815713A4 (en) 2022-04-06
EP3818990A1 (en) 2021-05-12
JP2021529789A (ja) 2021-11-04
JP7296644B2 (ja) 2023-06-23
MX2021000002A (es) 2021-05-12
CA3105283A1 (en) 2020-01-02
SG11202013183UA (en) 2021-01-28
WO2020001587A1 (zh) 2020-01-02
CA3105281A1 (en) 2020-01-02
US12178871B2 (en) 2024-12-31
WO2020001596A1 (zh) 2020-01-02
AU2019296320A1 (en) 2021-01-28
BR112020026976A2 (pt) 2021-05-25
US20220072124A1 (en) 2022-03-10
KR102704088B1 (ko) 2024-09-09
EP3815713A1 (en) 2021-05-05
US20230210893A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
Song et al. Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma
Tamayo et al. Poly (anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation
CN108743938B (zh) 用于增强免疫响应的复合物的制备方法
CN109078180B (zh) 用于增强免疫响应的复合物
WO2014075631A1 (zh) 一种自体肿瘤疫苗的制备方法及其应用
Xu et al. In vivo immunological activity of chitosan-derived nanoparticles
US12178871B2 (en) Complex for enhancing immune response
JP2015512441A (ja) 経口ワクチン投与のための改善アジュバント系
CN107200788B (zh) 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用
CN116763725A (zh) 一种智能响应型可注射水凝胶及其制备方法和应用
US20230233461A1 (en) Anti-infection and anti-tumor mucosal immune preparation
RU2779622C9 (ru) Комплекс для усиления иммунного ответа
RU2779622C2 (ru) Комплекс для усиления иммунного ответа
HK40042700A (en) Complex for enhancing immune response
US20250049951A1 (en) Nucleic acid compositions and uses thereof
RU2396978C1 (ru) Способ профилактики развития лейкоза крупного рогатого скота
Christodoulou et al. Al-fumarate, a Metal-Organic Framework encapsulating antigen as a potent, versatile and resorbable vaccine adjuvant
CN102058879B (zh) 一种口服肿瘤纳米疫苗及其构建方法
Rosales-Mendoza et al. Silica-based mucosal nanovaccines
EA042873B1 (ru) Средство для профилактики вирусных инфекций
JP2008127324A (ja) キャリア

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BEIJING YISHENG BIOTECHNOLOGY CO., LTD.

Free format text: FORMER OWNER(S): XINFU (BEIJING) MEDICAL TECHNOLOGY CO., LTD.